摘要:
The present invention relates to compounds of the following formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).
摘要:
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.
摘要:
The present invention relates to compounds of the following formulae I and II that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). Formula (I ), Formula (Il)
摘要:
The present invention relates to a method of making tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate through the intermediacy of one or more of diethyl (R)-2-(1-(tert- butoxycarbonyl)pyrrolidin-3-yl)malonate, (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)malonic acid, tert-butyl (R)-3-(2-hydroxyethyl)pyrrolidine-1 -carboxylate, and test-butyl (R)-3-(2- iodoethyl)pyrrolidine- 1 -carboxylate.
摘要:
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions.
摘要:
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors (NNRs), to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). The present invention includes compounds which bind with high affinity to NNRs of either the α4β2 subtype, or the α6-containing subtype, or both NNR subtypes. Formula (I), wherein: each m is identical and is 0 or 1; each n is identical and is 0 or 1; when each m is 0, then each n is 1; when each m is 1, then each n is 0; R 1 is -C(O)-R 3 , -C(O)O-R 3 , -C(O)NH-R 3 , -C(O)-(CH 2 ) q -X-R 3 , -C(O)O-(CH 2 ) q -X-R 3 , or -C(O)NH-(CH 2 ) q -X-R 3 ; q is 1, 2, 3, 4, 5, or 6; X is -0-, -S-, -NH-, or -NHC(O)-; R 2 is H or alkyl; R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heterocyclic.